| This report contains COVID-19 specific updates.
Cancer Vaccines: Technologies and Global Markets
Report Highlights
The global market for cancer vaccines should grow from $8.1 billion in 2021 to $11.7 billion by 2026 with a compound annual growth rate (CAGR) of 7.6% for the period of 2021-2026.
Report Includes
- 20 data tables and 23 additional tables
- An overview of the global markets and technologies for cancer vaccines
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Detailed description of history, management, and causes of cancer including genetic factors, lifestyle factors and environmental factors, and information on types of cancer-causing genes
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast, and an overview of current and future dynamics of the global market for various cancer vaccines
- Discussion on present and future strategies within the cancer vaccines market, and comparative assessment of prophylactic vaccines and therapeutic vaccines
- Coverage of approved cancer vaccines, recalls, fast track designations and orphan drug designation and analysis of pipeline products and patents
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players of the industry, including Amgen Inc., Dendreon Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc. and Vaccinogen Inc.
Report Scope
The scope of this study involves the global market of cancer vaccines. The report covers the entire market of cancer vaccines, which includes two main areas of application, prophylactic vaccines and therapeutic vaccines. Discussion of human papillomavirus vaccines and hepatitis B vaccines that indirectly act against cancer is also included in the report.
Based on application, the market covers various cancer types such as prostate, liver, cervical, lung and bladder. Both marketing and research and development (R&D) perspectives are discussed in the report.
By geography, the market has been divided into four regions: North America, Europe, Asia-Pacific and Rest of the World. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered in regional segments. For market estimates, data have been provided for the year 2020 as the base year, with forecasts for 2021 through 2026.
Patent analysis, clinical trials, innovative research and opportunities of the newest trends within the cancer vaccine market and comprehensive profiles of companies that lead the cancer vaccine industry are also discussed.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
Report Highlights
The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.
Report Includes
- An overview of the global markets and technologies for cancer vaccines.
- Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of CAGRs through 2021.
- Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
- Examination of the governmental and regulatory environment and how its effecting the market.
- Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
- Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
- Relevant patent analysis, presented by year and by vaccine type.
- Profiles of major players in the industry.
Report Highlights
The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.
Report Includes
- An overview of the global markets and technologies for cancer vaccines.
- Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
- Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
- Examination of the governmental and regulatory environment and how its effecting the market.
- Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
- Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
- Relevant patent analysis, presented by year and by vaccine type.